Clinical Trial Update: Biomarker and DNA Collection in Subjects Participating in Protocol 22003

View source ↗

Summary

Clinical trial update for Protocol 22003 notes biomarker collection and DNA sampling in subjects with Fragile X syndrome; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Status: COMPLETED